Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: A phase I clinical trial including correlative studies

Authors

Erik H P van Putten, Erasmus University Medical Center
David T Curiel, Washington University School of Medicine in St. Louis
et al

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

4-14-2022

Volume

28

Issue

8

First Page

1572

Last Page

1585

Document Type

Open Access Publication

DOI

10.1158/1078-0432.CCR-21-3324

Rights and Permissions

van Putten EHP, Kleijn A, van Beusechem VW, Noske D, Lamers CHJ, de Goede AL, Idema S, Hoefnagel D, Kloezeman JJ, Fueyo J, Lang FF, Teunissen CE, Vernhout RM, Bakker C, Gerritsen W, Curiel DT, Vulto A, Lamfers MLM, Dirven CMF. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. Clin Cancer Res. 2022 Apr 14;28(8):1572-1585. doi.org/10.1158/1078-0432.CCR-21-3324 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.

Recommended Citation

van Putten, Erik H P; Curiel, David T; and et al, "Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: A phase I clinical trial including correlative studies." Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 8. 1572 - 1585. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11876